Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.21
BRKR's Cash-to-Debt is ranked lower than
61% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. BRKR: 1.21 )
Ranked among companies with meaningful Cash-to-Debt only.
BRKR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 1.39 Max: N/A
Current: 1.21
Equity-to-Asset 0.39
BRKR's Equity-to-Asset is ranked lower than
77% of the 216 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. BRKR: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
BRKR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.42 Max: 0.69
Current: 0.39
0.14
0.69
Interest Coverage 13.39
BRKR's Interest Coverage is ranked lower than
63% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. BRKR: 13.39 )
Ranked among companies with meaningful Interest Coverage only.
BRKR' s Interest Coverage Range Over the Past 10 Years
Min: 7.92  Med: 12.32 Max: 59.87
Current: 13.39
7.92
59.87
Piotroski F-Score: 8
Altman Z-Score: 4.30
Beneish M-Score: -2.61
WACC vs ROIC
9.62%
24.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 11.15
BRKR's Operating Margin % is ranked higher than
70% of the 221 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. BRKR: 11.15 )
Ranked among companies with meaningful Operating Margin % only.
BRKR' s Operating Margin % Range Over the Past 10 Years
Min: 5.83  Med: 9.6 Max: 13.34
Current: 11.15
5.83
13.34
Net Margin % 9.35
BRKR's Net Margin % is ranked higher than
79% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. BRKR: 9.35 )
Ranked among companies with meaningful Net Margin % only.
BRKR' s Net Margin % Range Over the Past 10 Years
Min: 3.13  Med: 6.06 Max: 9.58
Current: 9.35
3.13
9.58
ROE % 21.84
BRKR's ROE % is ranked higher than
90% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. BRKR: 21.84 )
Ranked among companies with meaningful ROE % only.
BRKR' s ROE % Range Over the Past 10 Years
Min: 7.03  Med: 14.91 Max: 23.93
Current: 21.84
7.03
23.93
ROA % 8.51
BRKR's ROA % is ranked higher than
83% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. BRKR: 8.51 )
Ranked among companies with meaningful ROA % only.
BRKR' s ROA % Range Over the Past 10 Years
Min: 2.94  Med: 5.66 Max: 11.34
Current: 8.51
2.94
11.34
ROC (Joel Greenblatt) % 37.27
BRKR's ROC (Joel Greenblatt) % is ranked higher than
77% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.64 vs. BRKR: 37.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BRKR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 19.4  Med: 30.31 Max: 54.93
Current: 37.27
19.4
54.93
3-Year Revenue Growth Rate -3.10
BRKR's 3-Year Revenue Growth Rate is ranked lower than
71% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. BRKR: -3.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BRKR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.75 Max: 43.4
Current: -3.1
0
43.4
3-Year EBITDA Growth Rate 8.50
BRKR's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. BRKR: 8.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BRKR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.45 Max: 145.1
Current: 8.5
0
145.1
3-Year EPS without NRI Growth Rate 25.60
BRKR's 3-Year EPS without NRI Growth Rate is ranked higher than
78% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. BRKR: 25.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BRKR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.1 Max: 59.6
Current: 25.6
0
59.6
GuruFocus has detected 4 Warning Signs with Bruker Corp $BRKR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BRKR's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NYSE:CRL, OTCPK:CZMWY, NAS:PRAH, NAS:PRXL, NAS:ICLR, NYSE:ALR, NAS:VWR, OTCPK:SWTUY, NAS:EXAS, NAS:CPHD, NYSE:BIO, NAS:DXCM, NAS:INCR, NAS:NEOG, OTCPK:MRCHF, NYSE:PKI, NAS:MYGN, NAS:QGEN, NAS:AXDX, NAS:FMI » details
Traded in other countries:BKD.Germany,
Headquarter Location:USA
Bruker Corp is a developer, manufacturer and distributor of scientific instruments and analytical and dignostic solutions that enable customers to explore life and materials at microscopic, molecular and cellular levels.

Bruker Corp was incorporated in Delaware and is a designer and manufacturer of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of customers in life science, pharmaceutical, biotechnological, clinical and molecular diagnostics research, and materials and chemical analysis in various industries and government applications. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas chromatography technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, and infrared and Raman molecular spectroscopy technologies. The Company manufactures and distributes field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. It also designs, manufactures and markets high and low temperature superconducting materials and devices based on metallic low temperature superconductors. The Company is organized into four operating segments: the Bruker BioSpin Group, the Bruker CALID Group, the Bruker MAT Group, and Bruker Energy & Supercon Technologies division. The Bruker BioSpin Group combines the Bruker Magnetic Resonance and Preclinical Imaging divisions and designs, manufactures and distributes enabling life science tools based on magnetic resonance and preclinical imaging technologies. The Bruker CALID Group combines the Bruker Life Sciences and Clinical, Bruker Chemical and Applied Markets, Bruker Detection and Bruker Optics divisions. It designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as Chemical, Biological, Radiological, Nuclear and Explosive detection products and instruments based on Raman molecular spectroscopy technologies. The Bruker MAT Group combines the Bruker AXS, Bruker Nano Surfaces, Bruker Nano Analytics and Bruker Elemental divisions and designs, manufactures and distributes spectroscopy and microscopy instruments for the analysis of composition and structure in material science and life science samples. The Bruker Energy & Supercon Technologies division develops and produces low temperature superconductor and high temperature superconductor materials for use in magnet technology and energy applications as well as linear accelerators, accelerator cavities, insertion devices, other accelerator components and specialty superconducting magnets for physics and energy research and a variety of other scientific applications. Company maintains direct sales forces throughout North America, Europe, Japan, Asia Pacific and Australia. It also utilizes indirect sales channels to reach customers. It also has various international distributors, independent sales representatives, and various other representatives in parts of Asia, Latin America, and Eastern Europe. Compa

Ratios

vs
industry
vs
history
PE Ratio 31.89
BRKR's PE Ratio is ranked higher than
62% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.35 vs. BRKR: 31.89 )
Ranked among companies with meaningful PE Ratio only.
BRKR' s PE Ratio Range Over the Past 10 Years
Min: 7.21  Med: 30.56 Max: 67.25
Current: 31.89
7.21
67.25
Forward PE Ratio 27.17
BRKR's Forward PE Ratio is ranked lower than
53% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.63 vs. BRKR: 27.17 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 31.89
BRKR's PE Ratio without NRI is ranked higher than
62% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.61 vs. BRKR: 31.89 )
Ranked among companies with meaningful PE Ratio without NRI only.
BRKR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.21  Med: 30.56 Max: 67.25
Current: 31.89
7.21
67.25
Price-to-Owner-Earnings 44.68
BRKR's Price-to-Owner-Earnings is ranked lower than
62% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.37 vs. BRKR: 44.68 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BRKR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.85  Med: 42.57 Max: 6933.33
Current: 44.68
10.85
6933.33
PB Ratio 6.62
BRKR's PB Ratio is ranked lower than
73% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. BRKR: 6.62 )
Ranked among companies with meaningful PB Ratio only.
BRKR' s PB Ratio Range Over the Past 10 Years
Min: 1.61  Med: 4.43 Max: 8.92
Current: 6.62
1.61
8.92
PS Ratio 2.98
BRKR's PS Ratio is ranked higher than
61% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. BRKR: 2.98 )
Ranked among companies with meaningful PS Ratio only.
BRKR' s PS Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.84 Max: 2.99
Current: 2.98
0.5
2.99
Price-to-Free-Cash-Flow 35.27
BRKR's Price-to-Free-Cash-Flow is ranked lower than
62% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.66 vs. BRKR: 35.27 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BRKR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.25  Med: 27.79 Max: 147.38
Current: 35.27
10.25
147.38
Price-to-Operating-Cash-Flow 27.23
BRKR's Price-to-Operating-Cash-Flow is ranked lower than
66% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.27 vs. BRKR: 27.23 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BRKR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.71  Med: 20.59 Max: 50.96
Current: 27.23
5.71
50.96
EV-to-EBIT 24.29
BRKR's EV-to-EBIT is ranked higher than
60% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.02 vs. BRKR: 24.29 )
Ranked among companies with meaningful EV-to-EBIT only.
BRKR' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.2  Med: 19.6 Max: 36.2
Current: 24.29
5.2
36.2
EV-to-EBITDA 18.84
BRKR's EV-to-EBITDA is ranked higher than
59% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.53 vs. BRKR: 18.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
BRKR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.7  Med: 16 Max: 36.2
Current: 18.84
4.7
36.2
PEG Ratio 18.76
BRKR's PEG Ratio is ranked lower than
86% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. BRKR: 18.76 )
Ranked among companies with meaningful PEG Ratio only.
BRKR' s PEG Ratio Range Over the Past 10 Years
Min: 0.09  Med: 1.17 Max: 25.38
Current: 18.76
0.09
25.38
Shiller PE Ratio 49.89
BRKR's Shiller PE Ratio is ranked higher than
52% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 46.11 vs. BRKR: 49.89 )
Ranked among companies with meaningful Shiller PE Ratio only.
BRKR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 35.83  Med: 50.04 Max: 101.93
Current: 49.89
35.83
101.93
Current Ratio 2.46
BRKR's Current Ratio is ranked lower than
53% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.72 vs. BRKR: 2.46 )
Ranked among companies with meaningful Current Ratio only.
BRKR' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.2 Max: 4.99
Current: 2.46
1.26
4.99
Quick Ratio 1.53
BRKR's Quick Ratio is ranked lower than
64% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BRKR: 1.53 )
Ranked among companies with meaningful Quick Ratio only.
BRKR' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1.29 Max: 3.95
Current: 1.53
0.43
3.95
Days Inventory 195.88
BRKR's Days Inventory is ranked lower than
87% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. BRKR: 195.88 )
Ranked among companies with meaningful Days Inventory only.
BRKR' s Days Inventory Range Over the Past 10 Years
Min: 179.35  Med: 216.33 Max: 264.16
Current: 195.88
179.35
264.16
Days Sales Outstanding 50.76
BRKR's Days Sales Outstanding is ranked higher than
66% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.14 vs. BRKR: 50.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
BRKR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.76  Med: 59.73 Max: 65.48
Current: 50.76
52.76
65.48
Days Payable 39.79
BRKR's Days Payable is ranked lower than
66% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.94 vs. BRKR: 39.79 )
Ranked among companies with meaningful Days Payable only.
BRKR' s Days Payable Range Over the Past 10 Years
Min: 26.4  Med: 29.9 Max: 147.25
Current: 39.79
26.4
147.25

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.53
BRKR's Dividend Yield % is ranked lower than
63% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. BRKR: 0.53 )
Ranked among companies with meaningful Dividend Yield % only.
BRKR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.14  Med: 0.55 Max: 0.76
Current: 0.53
0.14
0.76
Dividend Payout Ratio 0.17
BRKR's Dividend Payout Ratio is ranked higher than
73% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. BRKR: 0.17 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BRKR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.17  Med: 0.17 Max: 0.17
Current: 0.17
Forward Dividend Yield % 0.53
BRKR's Forward Dividend Yield % is ranked lower than
72% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. BRKR: 0.53 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.54
BRKR's 5-Year Yield-on-Cost % is ranked lower than
75% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.25 vs. BRKR: 0.54 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BRKR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.14  Med: 0.55 Max: 0.76
Current: 0.54
0.14
0.76
3-Year Average Share Buyback Ratio 1.60
BRKR's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. BRKR: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BRKR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.1  Med: -5.85 Max: 0
Current: 1.6
-22.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 32.24
BRKR's Price-to-Net-Current-Asset-Value is ranked lower than
86% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.67 vs. BRKR: 32.24 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BRKR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.43  Med: 12.94 Max: 103.75
Current: 32.24
2.43
103.75
Price-to-Tangible-Book 9.84
BRKR's Price-to-Tangible-Book is ranked lower than
72% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.04 vs. BRKR: 9.84 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BRKR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.35  Med: 5.52 Max: 20.43
Current: 9.84
1.35
20.43
Price-to-Intrinsic-Value-Projected-FCF 3.11
BRKR's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
55% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. BRKR: 3.11 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BRKR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.91  Med: 2.12 Max: 10.62
Current: 3.11
0.91
10.62
Price-to-Median-PS-Value 1.62
BRKR's Price-to-Median-PS-Value is ranked lower than
78% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. BRKR: 1.62 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BRKR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 0.96 Max: 22.64
Current: 1.62
0.33
22.64
Price-to-Graham-Number 3.74
BRKR's Price-to-Graham-Number is ranked higher than
51% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. BRKR: 3.74 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BRKR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.07  Med: 3.07 Max: 15.92
Current: 3.74
1.07
15.92
Earnings Yield (Greenblatt) % 4.12
BRKR's Earnings Yield (Greenblatt) % is ranked higher than
81% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. BRKR: 4.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BRKR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 5.1 Max: 19.4
Current: 4.12
2.8
19.4
Forward Rate of Return (Yacktman) % 3.27
BRKR's Forward Rate of Return (Yacktman) % is ranked lower than
65% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. BRKR: 3.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BRKR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2  Med: 9.4 Max: 110.4
Current: 3.27
-2
110.4

More Statistics

Revenue (TTM) (Mil) $1,620.80
EPS (TTM) $ 0.94
Beta1.32
Short Percentage of Float3.60%
52-Week Range $19.59 - 28.69
Shares Outstanding (Mil)159.94

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,655 1,722 1,791
EPS ($) 1.10 1.22 1.36
EPS without NRI ($) 1.10 1.22 1.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.08 0.08 0.08
» More Articles for BRKR

Headlines

Articles On GuruFocus.com
ID Watchdog Announces Special and Annual General Meeting Date and Record Date Jun 23 2017 
Ironclad Performance Wear Postpones 2017 Annual Meeting of Stockholders Jun 23 2017 
Delta and Korean Air Create Leading trans-Pacific Joint Venture Jun 23 2017 
Harwood Feffer LLP Announces Investigation of EnerNOC, Inc. Jun 23 2017 
Charles D. Christy Named Chief Financial Officer Jun 23 2017 
Harwood Feffer LLP Announces Investigation of CardConnect Corp. Jun 23 2017 
eCobalt Provides Feasibility Study Update on the Idaho Cobalt Project Jun 23 2017 
Tanger Outlet Centers Schedules Second Quarter 2017 Earnings Release and Conference Call Jun 23 2017 
Cortelco Systems Puerto Rico, Inc. Board of Directors Authorizes Dividend Jun 23 2017 
Take-Two Is Set to Soar Higher Jun 23 2017 

More From Other Websites
Edited Transcript of BRKR earnings conference call or presentation 3-May-17 8:45pm GMT Jun 14 2017
Bruker Grows on NMR & Nano Businesses amid Several Odds Jun 08 2017
Bruker (BRKR) Up 7.7% Since Earnings Report: Can It Continue? Jun 05 2017
Bruker Introduces Novel Mass Spectrometry Solutions for MALDI Imaging, Metabolomics, Proteoform... Jun 05 2017
Bruker Corp. : BRKR-US: Dividend Analysis : June 05th, 2017 (record date) : By the numbers : June 2,... Jun 02 2017
Bruker Corporation to Present at Investor Conferences Jun 02 2017
Bruker Introduces New Solutions for Microbial Strain Typing, Hospital Hygiene and Infection Control... Jun 01 2017
Bruker Corp (BRKR) at 52-Week High: What's Driving the Stock? May 23 2017
Bruker Corp. :BRKR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 23, 2017 May 23 2017
Weekly CEO Buys Highlights May 22 2017
Bruker Launches the S8 TIGER™ Series 2 WDXRF System for Elemental Analysis in Industrial and... May 22 2017
Bruker Announces New $225 Million Share Repurchase Program and Quarterly Dividend May 12 2017
Bruker Acquires Emerging Light Sheet Microscopy Company Luxendo May 08 2017
Bruker (BRKR) Q1 Earnings Meet, Revenues Beat Estimates May 04 2017
Bruker meets 1Q profit forecasts May 03 2017
Bruker Reports First Quarter 2017 Financial Results May 03 2017
Investor Network: Bruker Corporation to Host Earnings Call May 03 2017
Bruker Corp. – Value Analysis (NASDAQ:BRKR) : May 1, 2017 May 01 2017
Bruker Corp. breached its 50 day moving average in a Bullish Manner : BRKR-US : April 28, 2017 Apr 28 2017
Bruker Corporation to Present at the 42nd Annual Deutsche Bank Health Care Conference Apr 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}